An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

This open-label, Phase IIa study (n=12) evaluates the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 (5-MeO-DMT) combined with relapse prevention psychological support for patients with Alcohol Use Disorder (AUD).

Conducted by Beckley Psytech Ltd, the trial aims to explore the potential effects of BPL-003 on alcohol use and related symptoms. Approximately 12 eligible participants will receive a single intranasal dose of BPL-003, with 12 weeks of follow-up assessments. Psychological support will be provided before, during, and after dosing.

The study started on May 30, 2023, and was estimated to be completed by October 2023.

Trial Details

An open-label, Phase IIa study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.

NCT Number NCT05674929

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.